Device and methods for the immunological identification of cerebrospinal fluid
AssigneeAffinimark Technologies, Inc.,
InventorVincent Pieribone
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample by the detection of one or more antigens that are enriched in CSF compared to their levels in other bodily fluids. The devices and methods are suitable for the detection of the presence or absence of cerebrospinal fluid in samples of mixed bodily fluids from a wide variety of human populations crossing ethnicity, age, gender, health status and genetic variability.
Claims19
A device for detection of the presence or absence of cerebrospinal fluid in a sample, comprising
- a sample application region,
- a sample labeling region comprising a first antibody to a CSF-enriched protein, wherein the first antibody is conjugated to a mobile particle;
- a sample detection region comprising a second antibody to the CSF-enriched protein, wherein the second antibody is fixed to the sample detection region,
- wherein the presence of a detectable band in the sample detection region indicates the presence of cerebrospinal fluid in the sample, wherein the CSF-enriched protein is selected from the group consisting of CNTN2 Contactin-2 precursor (SEQ ID NO:
- 3;
- Accession Number gi|4827022);
- cDNA FLJ59893, dickkopf homolog 3 precursor (SEQ ID NO:
- 13;
- Accession Number gi|40548389);
- CADM3 Homo sapiens cell adhesion molecule 3 (CADM3), transcript variant 1 (SEQ ID NO:
- 17;
- Neural cell adhesion molecule variant (SEQ ID NO:
- 19;
- Accession Number gi:62088238);
- a CSF-enriched phosphorylated or dephosphorylated form of the foregoing CSF antigens;
- and a combination of two or more of the foregoing CSF antigens.
A method for detecting the presence or absence of CSF in a sample, comprising
- contacting the sample with a binding partner specific for a CSF-enriched protein, and
- detecting binding partner-CSF-enriched protein complexes if present, wherein the presence of detectable complexes indicates the presence of CSF in the sample;
- wherein the CSF-enriched protein is selected from the group consisting of CNTN2 Contactin-2 precursor (SEQ ID NO:
- 3;
- Accession Number gi|1827022);
- NRCAM protein (Neuronal cell adhesion molecule)[Homo sapiens] possibly slightly longer fragment (˜96 kDa) SEQ ID NO:
- 7;
- gi|109731501);
- cDNA FLJ59893, dickkopf homolog 3 precursor (SEQ ID NO:
- 13;
- Accession Number gi|40548389);
- CADM3 Homo sapiens cell adhesion molecule 3 (CADM3), transcript variant 1 (SEQ ID NO:
- 17;
- Neural cell adhesion molecule variant (SEQ ID NO:
- 19;
- Accession Number gi:62088238);
- a CSF-enriched phosphorylated or dephosphorylated form of the foregoing CSF antigens;
- and a combination of two or more of the foregoing CSF antigens.
A method for the detection of a reactant in a body fluid, tissue or microorganism, comprising
- contacting the body fluid, tissue or microorganism with two or more antibodies, wherein each antibody specifically reacts with an antigen in the reactant,
- wherein reaction with each individual antibody does not indicate a positive test for the reactant, and
- wherein reaction with the two or more antibodies indicates a positive test for the reactant.
Dependencies are inferred from the claim text.